The EC has authorised the use of ViiV Healthcare’s Vocabria plus Rekambys from J&J for treating adolescents with HIV-1.

The U.S. Department of Health & Human Services may seek over $1 billion from Johnson & Johnson as reimbursement for federal ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

Kenvue's improvements in marketing and management could drive future growth. Read why there is potential for a turnaround for ...

J&J Chief Financial Officer Joe Wolk said on ... Editing by Stephen Coates and Nick Zieminski Bhanvi Satija reports on pharmaceutical companies and the healthcare industry in the United States.

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not respond to ...

B Health and two safety-net hospitals want to help the government prove that drugmakers are required to give upfront ...

As the nation kicks off Black History Month, a look into the industry shows there is a significant lack of Black leaders.

Biljana Naumovic discusses the importance of finding ways to reach out to underserved communites.

Major stock indexes closed higher/lower on Friday, after the week saw a flurry of events including DeepSeek scare and ...

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...